Evusheld FDA Approval Status
Last updated by Judith Stewart, BPharm on Dec 16, 2024.
FDA Approved: No (Discontinued)
Brand name: Evusheld
Generic name: tixagevimab co-packaged with cilgavimab
Dosage form: Injection
Previous Name: AZD7442
Company: AstraZeneca
Treatment for: Pre-Exposure Prophylaxis of COVID-19
Evusheld (tixagevimab co-packaged with cilgavimab) is a long-acting antibody (LAAB) combination authorized for emergency use for pre-exposure prophylaxis of COVID-19.
UPDATE: FDA Announces Evusheld is Not Currently Authorized for Emergency Use in the U.S.
January 26, 2023 -- Evusheld is not currently authorized in any U.S. region due to the high frequency of circulating SARS-CoV-2 variants that are non-susceptible to Evusheld. Therefore, Evusheld may not be administered for pre-exposure prophylaxis for prevention of COVID-19 under the Emergency Use Authorization until further notice by the Agency.
November 21, 2024 -- AstraZeneca requested that the U.S. Food and Drug Administration revoke the Emergency Use Authorization for Evusheld (tixagevimab co-packaged with cilgavimab) since all lots of Evusheld distributed under EUA 104 have expired.
- The Food and Drug Administration (FDA) has granted emergency use authorisation (EUA) for Evusheld for pre-exposure prophylaxis of COVID-19 in adults and adolescents (aged 12 and older who weigh 40kg or more) for preexposure prophylaxis for prevention of COVID-19 in persons who are:
- not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARSCoV-2 and
- Who have moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination or
- For whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction (e.g., severe allergic reaction) to a COVID-19 vaccine(s) and/or COVID19 vaccine component(s).
- not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARSCoV-2 and
- The monoclonal antibodies in Evusheld are designed to attach to the spike protein of the SARS-CoV-2 virus, to stop the virus from entering the cells to cause COVID-19 infection. Proprietary half-life extension technology increases the durability of action compared to conventional monoclonal antibodies, and the combination of LAABs is designed to reduce the risk of resistance developed by the SARS-CoV-2 virus and its variants.
- Evusheld is the first monoclonal antibody therapy authorised by the FDA for pre-exposure prophylaxis of COVID-19. Other monoclonal antibody therapies are authorised for post-exposure prophylaxis.
- Evusheld is derived from B-cells donated by convalescent patients after SARS-CoV-2 virus. It is administered intramuscularly as two separate, consecutive injections.
- Data from the Phase III PROVENT trial demonstrated protection against COVID-19 lasting for at least six months following a single administration.
- Evusheld may cause serious adverse reactions including hypersensitivity reactions (including anaphylaxis), bleeding disorders, and cardiovascular events. Common adverse reactions include headache, fatigue, and cough.
Development timeline for Evusheld
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.